logo-amri - Eagle Pharmaceuticals

logo-amri

Posted August 16, 2017

In

Recent Posts

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
Eagle Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
The U.S. Food & Drug Administration Accepts Eagle Pharmaceuticals’ Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia
Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular Formulation of ENA-001

Leave a Comment

You must be logged in to post a comment.

Cookie Settings

We use cookies to analyze website usage and assist our marketing efforts. Your cookie preference will be stored on your browser, and is categorized as a "Necessary" cookie. Third-party cookies we use to collect website analytics will be stored in your browser only with your consent. You also have the option to opt-out of these cookies using the tool below.

Privacy Policy
Cookie Policy
Notice to California Residents

Necessary

Always Enabled

Necessary cookies store cookie preferences made here in the cookie settings tools.

Cookie	Duration	Description
Cookie Preference	11 months	This cookie is used to store cookie preferences made here in the cookie settings tool.

Analytical cookies are used to understand how visitors interact with the website. These cookies provide information about the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
Google Analytics	11 months	A unique identifier given to each browser to track user interactions with the website.